Capivasertib China PK study

Trial Identifier: D3614C00002
Sponsor: AstraZeneca
NCTID:: NCT04742036
Start Date: February 2021
Primary Completion Date: July 2022
Study Completion Date: July 2022
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese (China) Translation

Trial Locations